CD4 and cancer: Of these, the MHC II-restricted peptide-epitope, NY-ESO-187-111-specific CD4+ T-cell was characterized in the context of HLA-DRB3*0101, indicating that bvPLA2m allows NY(s) presentation by the DCs without impairing the processing of the natural cancer/testis antigen, NY-ESO-1.